DDInter463 DDInter1435
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
Dacarbazine {u} (Compound) binds {v} (Gene) POLA2
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
Dacarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Dacarbazine {u} (Compound) downregulates {v} (Gene) HMGCS1
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Dacarbazine {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Dacarbazine (Compound) treats skin cancer (Disease)
Dacarbazine (Compound) binds POLA2 (Gene)
Dacarbazine (Compound) upregulates CADM1 (Gene)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Dacarbazine (Compound) downregulates HMGCS1 (Gene)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin